JP6483148B2 - ＨＰＴＰ−β阻害剤 - Google Patents

ＨＰＴＰ−β阻害剤 Download PDF

Info

Publication number
JP6483148B2
JP6483148B2 JP2016556997A JP2016556997A JP6483148B2 JP 6483148 B2 JP6483148 B2 JP 6483148B2 JP 2016556997 A JP2016556997 A JP 2016556997A JP 2016556997 A JP2016556997 A JP 2016556997A JP 6483148 B2 JP6483148 B2 JP 6483148B2
Authority
JP
Japan
Prior art keywords
substituted
compound
bond
unsubstituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016556997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511305A (ja
JP2017511305A5 (enExample
Inventor
ジョン ジャヌス，
ジョン ジャヌス，
ジェイムズ コップ，
ジェイムズ コップ，
ケビン ピータース，
ケビン ピータース，
Original Assignee
エアーピオ セラピューティクス インコーポレイテッド
エアーピオ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エアーピオ セラピューティクス インコーポレイテッド, エアーピオ セラピューティクス インコーポレイテッド filed Critical エアーピオ セラピューティクス インコーポレイテッド
Publication of JP2017511305A publication Critical patent/JP2017511305A/ja
Publication of JP2017511305A5 publication Critical patent/JP2017511305A5/ja
Application granted granted Critical
Publication of JP6483148B2 publication Critical patent/JP6483148B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016556997A 2014-03-14 2015-03-13 ＨＰＴＰ−β阻害剤 Active JP6483148B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461953680P 2014-03-14 2014-03-14
US61/953,680 2014-03-14
PCT/US2015/020425 WO2015138882A1 (en) 2014-03-14 2015-03-13 Hptp-beta inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018246712A Division JP6661744B2 (ja) 2014-03-14 2018-12-28 ＨＰＴＰ−β阻害剤

Publications (3)

Publication Number Publication Date
JP2017511305A JP2017511305A (ja) 2017-04-20
JP2017511305A5 JP2017511305A5 (enExample) 2018-04-12
JP6483148B2 true JP6483148B2 (ja) 2019-03-13

Family

ID=54068203

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016556997A Active JP6483148B2 (ja) 2014-03-14 2015-03-13 ＨＰＴＰ−β阻害剤
JP2018246712A Active JP6661744B2 (ja) 2014-03-14 2018-12-28 ＨＰＴＰ−β阻害剤
JP2019077696A Withdrawn JP2019108407A (ja) 2014-03-14 2019-04-16 ＨＰＴＰ−β阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018246712A Active JP6661744B2 (ja) 2014-03-14 2018-12-28 ＨＰＴＰ−β阻害剤
JP2019077696A Withdrawn JP2019108407A (ja) 2014-03-14 2019-04-16 ＨＰＴＰ−β阻害剤

Country Status (5)

Country Link
US (3) US9994560B2 (enExample)
EP (1) EP3116503A4 (enExample)
JP (3) JP6483148B2 (enExample)
CN (1) CN106456614A (enExample)
WO (1) WO2015138882A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
PT2385763T (pt) * 2009-01-12 2018-07-13 Aerpio Therapeutics Inc Métodos para tratar o síndrome de extravasamento vascular
BRPI1006897A2 (pt) 2009-07-06 2015-09-08 Akebia Therapeutics Inc compostos, composições e métodos de prevenção da metástase de células cancerosas.
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
JP6572201B2 (ja) 2013-03-15 2019-09-04 エアーピオ セラピューティクス インコーポレイテッド 眼疾患を処置するための組成物、製剤、および方法
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
SG10201912556VA (en) 2016-07-20 2020-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
EP3759234A1 (en) * 2018-02-26 2021-01-06 Aerpio Pharmaceuticals, Inc. Methods of treating diabetic nephropathy using hptpss inhibitors
US20210283051A1 (en) * 2018-07-13 2021-09-16 Mannin Research, Inc. Ve-ptp inhibition in glaucoma
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
EP3956021A4 (en) * 2019-04-18 2023-06-14 EyePoint Pharmaceuticals, Inc. METHOD OF TREATMENT OF HIGH BLOOD PRESSURE WITH ACTIVATORS OF TIE-2
JP7564824B2 (ja) * 2019-04-29 2024-10-09 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
US11413242B2 (en) 2019-06-24 2022-08-16 EyePoint Pharmaceuticals, Inc. Formulations of Tie-2 activators and methods of use thereof
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11613534B2 (en) 2019-10-29 2023-03-28 EyePoint Pharmaceuticals, Inc. Small molecule activators of Tie-2
CN113060789A (zh) * 2019-12-31 2021-07-02 大连乾丰生物科技有限公司 一种海蜇池塘水底质改良剂
CN116940355A (zh) * 2020-12-18 2023-10-24 视点制药公司 用于制造tie-2的小分子激活剂的方法

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221584A (en) 1979-02-09 1980-09-09 Chevron Research Company Herbicidal and plant-growth-regulating N-(heterocyclyl)-methylacetanilides
US4735961A (en) 1984-05-07 1988-04-05 Merck & Co., Inc. Oxazoles and thiazoles containing an aminohydroxypropoxyphenyl moiety
MY113488A (en) * 1995-01-27 2002-03-30 Novo Nordisk As Compounds with growth hormone releasing properties
CA2216963C (en) 1995-04-06 2010-06-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligands, methods of making and uses thereof
US20030040463A1 (en) 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
WO1998018914A1 (en) 1996-10-31 1998-05-07 Duke University Soluble tie2 receptor
US5980929A (en) 1998-03-13 1999-11-09 Johns Hopkins University, School Of Medicine Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
US5919813C1 (en) 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
NZ514434A (en) 1999-03-26 2003-11-28 Univ California Modulation of vascular permeability by means of TIE2 receptor activators
PT1292335E (pt) 2000-06-23 2007-08-13 Bayer Schering Pharma Ag Combinações e composições que interferem na função de receptores vegf/vegf e angiopoietina/ tie e a sua utilização (ii)
AU2002335085A1 (en) 2001-10-25 2003-05-06 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
WO2003072100A1 (en) * 2002-02-25 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
WO2003084565A2 (en) 2002-04-08 2003-10-16 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Ve-ptp as regulator of ve-cadherin mediated processes or disorders
AU2003231098A1 (en) 2002-04-25 2003-11-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
US6946479B2 (en) 2002-11-09 2005-09-20 The Procter & Gamble Company N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
KR101166342B1 (ko) 2004-03-15 2012-07-18 얀센 파마슈티카 엔.브이. 아편계 약물 수용체 조절자로서의 신규의 화합물
CN1933833B (zh) * 2004-03-18 2011-09-07 株式会社·R-技术上野 含有噻唑衍生物的含水组合物
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
SI1771474T1 (sl) 2004-07-20 2010-06-30 Genentech Inc Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
EP1819355A4 (en) 2004-09-28 2009-08-12 Genexel Sein Inc METHOD OF USE OF A CHIMERIC COILED COIL MOLECULE
ZA200705695B (en) 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
EP1962903B1 (en) 2005-12-15 2013-03-13 MedImmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8957022B2 (en) 2006-10-27 2015-02-17 Sunnybrook Health Sciences Centre Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
CA2716347C (en) 2008-02-21 2017-06-20 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
PT2385763T (pt) * 2009-01-12 2018-07-13 Aerpio Therapeutics Inc Métodos para tratar o síndrome de extravasamento vascular
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
ES2508290T3 (es) 2009-03-03 2014-10-16 Alcon Research, Ltd. Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo
CN105362221A (zh) 2009-03-03 2016-03-02 爱尔康研究有限公司 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
BRPI1006897A2 (pt) 2009-07-06 2015-09-08 Akebia Therapeutics Inc compostos, composições e métodos de prevenção da metástase de células cancerosas.
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
CA2774039A1 (en) 2009-11-06 2011-05-12 Aerpio Therapeutics Inc. Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
US20110319455A1 (en) * 2010-04-19 2011-12-29 Bruce Steven Klein Antifungal Treatment
RU2597844C2 (ru) 2010-07-12 2016-09-20 Тресхолд Фармасьютикалз, Инк. Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака
US20180092883A1 (en) 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
CA2818215C (en) * 2010-10-07 2015-07-21 Aerpio Therapeutics Inc. Compositions and methods for treating ocular edema, neovascularization and related diseases
EP2857032A3 (en) 2010-12-02 2015-07-15 Maruzen Pharmaceuticals Co., Ltd. Tie2 activator, vascular endothelial growth factor (vegf) inhibitor, anti-angiogenic agent, agent for maturing blood vessels, agent for normalizing blood vessels, agent for stabilizing blood vessels, and pharmaceutical composition
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
EP3501536B1 (en) 2011-10-13 2025-12-24 EyePoint Pharmaceuticals, Inc. Treatment of ocular disease
US20130190324A1 (en) 2011-12-23 2013-07-25 The Regents Of The University Of Colorado, A Body Corporate Topical ocular drug delivery
WO2013155512A2 (en) 2012-04-13 2013-10-17 The Johns Hopkins University Treatment of ischemic retinopathies
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
SMT201800404T1 (it) 2012-07-31 2018-09-13 Univ Texas Metodi e composizioni per induzione in vivo di formazione di cellule beta pancreatiche
DK2906246T3 (da) 2012-10-11 2023-09-04 Ascendis Pharma Ophthalmology Div A/S VEGF-neutraliserende prodrugs omfattende ranibizumab til behandling af okulære tilstande, der er kendetegnet ved okulær neovaskularisering
AU2013342275B2 (en) 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
WO2014079709A1 (en) 2012-11-23 2014-05-30 Ab Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
JP6572201B2 (ja) 2013-03-15 2019-09-04 エアーピオ セラピューティクス インコーポレイテッド 眼疾患を処置するための組成物、製剤、および方法
CA2909080C (en) 2013-04-11 2022-07-26 Sunnybrook Research Institute Methods, uses and compositions of tie2 agonists
US20160130321A1 (en) 2013-06-20 2016-05-12 Gabriela Burian Use of a vegf antagonist in treating macular edema
JP2016522249A (ja) 2013-06-20 2016-07-28 ノバルティス アーゲー 脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用
US20160151410A1 (en) 2013-07-02 2016-06-02 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
BR112016000177A2 (pt) 2013-07-11 2017-12-12 Novartis Ag usos de um antagonista do vegf no tratamento de doenças neovasculares coriorretinianas e de permeabilidade em pacientes pediátricos, seringa pré-cheia, kit e formulação de liberação lenta
JP2016523956A (ja) 2013-07-11 2016-08-12 ノバルティス アーゲー 未熟児網膜症の治療におけるｖｅｇｆアンタゴニストの使用
US9902767B2 (en) 2013-07-29 2018-02-27 Samsung Electronics Co., Ltd. Method of blocking vascular leakage using an anti-ANG2 antibody
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
TR201905773T4 (tr) 2013-10-01 2019-05-21 Sphingotec Gmbh Bir majör advers kardiyak olayla karşılaşma riskinin tahmin edilmesi için bir usul.
CA2928852A1 (en) 2013-11-01 2015-05-07 Regeneron Pharmaceuticals, Inc. Angiopoietin-based interventions for treating cerebral malaria
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
JP2015199733A (ja) 2014-04-04 2015-11-12 国立大学法人東北大学 眼圧降下剤
US9719135B2 (en) 2014-07-03 2017-08-01 Mannin Research Inc. Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
US20160082129A1 (en) 2014-09-24 2016-03-24 Aerpio Therapeutics, Inc. VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases

Also Published As

Publication number Publication date
JP6661744B2 (ja) 2020-03-11
US9994560B2 (en) 2018-06-12
US20210130341A1 (en) 2021-05-06
US20180354937A1 (en) 2018-12-13
CN106456614A (zh) 2017-02-22
JP2019048894A (ja) 2019-03-28
US10858354B2 (en) 2020-12-08
JP2017511305A (ja) 2017-04-20
US20150259335A1 (en) 2015-09-17
JP2019108407A (ja) 2019-07-04
WO2015138882A1 (en) 2015-09-17
EP3116503A4 (en) 2017-08-23
EP3116503A1 (en) 2017-01-18

Similar Documents

Publication Publication Date Title
JP6661744B2 (ja) ＨＰＴＰ−β阻害剤
JP6865254B2 (ja) 眼疾患を処置するための組成物、製剤、および方法
KR101823924B1 (ko) 안구 부종, 신생혈관화 및 관련 질환의 치료를 위한 조성물 및 방법
JP6959924B2 (ja) Ｔｉｅ−２の活性化物質を用いる眼内圧を処置する方法
US20170172959A1 (en) D-serine for the treatment of visual system disorders
US12187715B2 (en) Small molecule activators of Tie-2
KR20120081585A (ko) 안질환을 치료하기 위한 이소티오졸
CA3138682A1 (en) Tie-2 activators targeting the schlemm's canal
US20250170143A1 (en) Methods of treating ocular fibrotic pathologies
JP7580123B2 (ja) 血管新生関連疾患の予防又は治療用医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181015

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190213

R150 Certificate of patent or registration of utility model

Ref document number: 6483148

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350